ClinicalTrials.gg
CompletedNCT04782076Updated May 24, 2024Results posted

A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants

A Phase 1 interventional study of Dabigatran and Selpercatinib in Healthy, sponsored by Loxo Oncology, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-24.

Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to determine the effect of selpercatinib on the levels of dabigatran in the blood stream and how long it takes the body to remove dabigatran. This study will also look at how safe and well-tolerated of dabigatran when administered in combination with selpercatinib in healthy participants. This study will last approximately 22 to 25 days.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Loxo Oncology, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

First submitted after Loxo Oncology, Inc. became part of Eli Lilly and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy males or females, as determined by medical history, physical examination and vital signs.
  • (BMI) within the range of 19 to 35 kilograms per meter squared (kg/m²)
  • Male participants are not required to adhere to requirements and female participants of must agree to be either remain abstinent or stay in a same sex relationship without sexual relationships with males or must agree to use a highly effective method of contraception and who underwent bilateral salpingectomy. The Female participants not of childbearing potential are not required to use contraception.

Exclusion criteria

Exclusion Criteria:

  • Have a positive pregnancy test at screening or Day -1, where applicable
  • Are planning to become pregnant during the study or within 1 month of study completion
  • Are women who are lactating
  • Have known allergies to selpercatinib- or dabigatran-related compounds or any components of the formulation of selpercatinib or dabigatran, or history of significant atopy
  • Have a history of allergic reactions to medications or food products
  • Have a abnormality of blood pressure and/or pulse rate as determined by the investigator
  • Have known bleeding disorder including prior personal or familiar history of abnormal bleeding, hereditary or acquired coagulation or disorder
  • Clinically significant abnormalities on as determined by the investigator or prolongation of the or QTcF >450 msec on more than 1 ECG obtained during screening only
  • Have clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to the planned start of selpercatinib
  • Are currently enrolled in any other clinical study involving an product or any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have an average weekly alcohol intake that exceeds 21 units per week (males ≤65 years old) and 14 units per week (females); 1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirit(s)
  • Are smokers of more than 10 cigarettes or e-cigarettes, or 3 cigars or 3 pipes, per day
  • Consume excessive amounts of coffee, tea, cola, or other caffeinated beverages per day
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Dabigatran + Selpercatinib

    Participants received a single oral dose of 150 milligrams (mg) dabigatran on Day 1 and a single oral dose of 150 mg dabigatran coadministered with a single oral dose of 2 x 80 mg (160 mg) selpercatinib on Day 8. There was a washout period of 7 days between dosing on Days 1 and 8.

    Drug: Dabigatran · Drug: Selpercatinib

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Dabigatran

    PK: Cmax of Dabigatran

    Time frame: Day 1 and Day 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hours (h) postdose

  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Dabigatran

    PK: AUC(0-inf) of Dabigatran

    Time frame: Day 1 and Day 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 h postdose

Secondary outcomes

  1. PK: Cmax of Selpercatinib

    PK: Cmax of Selpercatinib

    Time frame: Day 8: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 h postdose

  2. PK: AUC(0-inf) of Selpercatinib

    PK: AUC(0-inf) of Selpercatinib

    Time frame: Day 8: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 h postdose

  3. PK: Time of Maximum Observed Drug Concentration (Tmax) of Selpercatinib

    PK: Tmax of Selpercatinib

    Time frame: Day 8: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 h postdose

07

Results

Posted May 24, 2024

Participant flow

Participant flow — Overall Study
MilestoneDabigatran + Selpercatinib
Started36
Received at least one dose of dabigatran on day 136
Washout period36
Received at least one dose of selpercatinib and dabigatran on day 835
Completed35
Not completed1
Withdrew: Family emergency1

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Dabigatran

PK: Cmax of Dabigatran

Time frame:
Day 1 and Day 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hours (h) postdose
Reported as:
Geometric least squares mean · nanogram per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Dabigatran
nanogram per milliliter (ng/mL)DabigatranSelpercatinib + Dabigatran
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Dabigatran192 ± 41276 ± 36
Statistical analysis
  • Dabigatran vs Selpercatinib + Dabigatran · Mixed Models Analysis · Ls mean difference (final values): 1.43 · 90% CI 1.33 to 1.55Least Squares Mean (LS Mean)
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Dabigatran

PK: AUC(0-inf) of Dabigatran

Time frame:
Day 1 and Day 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 h postdose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Dabigatran
nanogram*hour per milliliter (ng*h/mL)DabigatranSelpercatinib + Dabigatran
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Dabigatran1650 ± 422290 ± 37
Statistical analysis
  • Dabigatran vs Selpercatinib + Dabigatran · Mixed Models Analysis · Ls mean difference (final values): 1.38 · 90% CI 1.30 to 1.46
SecondaryPK: Cmax of Selpercatinib

PK: Cmax of Selpercatinib

Time frame:
Day 8: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 h postdose
Reported as:
Geometric mean · ng/mL
PK: Cmax of Selpercatinib
ng/mLSelpercatinib + Dabigatran
PK: Cmax of Selpercatinib1830 ± 23
SecondaryPK: AUC(0-inf) of Selpercatinib

PK: AUC(0-inf) of Selpercatinib

Time frame:
Day 8: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 h postdose
Reported as:
Geometric mean · ng*h/mL
PK: AUC(0-inf) of Selpercatinib
ng*h/mLSelpercatinib + Dabigatran
PK: AUC(0-inf) of Selpercatinib25600 ± 27
SecondaryPK: Time of Maximum Observed Drug Concentration (Tmax) of Selpercatinib

PK: Tmax of Selpercatinib

Time frame:
Day 8: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 h postdose
Reported as:
Median · hours
PK: Time of Maximum Observed Drug Concentration (Tmax) of Selpercatinib
hoursSelpercatinib + Dabigatran
PK: Time of Maximum Observed Drug Concentration (Tmax) of Selpercatinib3.00 (1.50 to 6.00)

Adverse events

Collected over Baseline up to 25 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
150 mg Dabigatran0/36 (0%)0/36 (0%)0/36 (0%)
150 mg Dabigatran + 160 mg Selpercatinib0/35 (0%)0/35 (0%)0/35 (0%)

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Dabigatran + Selpercatinib
Mean42.5 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)Dabigatran + Selpercatinib
Female14
Male22
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dabigatran + Selpercatinib
Hispanic or Latino11
Not Hispanic or Latino25
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dabigatran + Selpercatinib
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American15
White20
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Dabigatran + Selpercatinib
United States36
08

Study locations

1 site
  • Covance Clinical Research Inc
    Daytona Beach, Florida 32117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in May 2021, 2 months.

Results were first posted in May 2024, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2021
First posted
Mar 4, 2021
StartActual
Mar 5, 2021
Primary completionActual
May 17, 2021
CompletionActual
May 17, 2021
Results first posted
May 24, 2024
Last update
May 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04782076
Responsible party
Sponsor
First posted
Mar 4, 2021
Start date
Mar 5, 2021
Primary completion
May 17, 2021
Completion
May 17, 2021
Results posted
May 24, 2024
Last update
May 24, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dabigatran · Selpercatinib

Start the discussion